Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…
ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization
Showcasing at AAO 2025: NEW 510k CLEARANCE SUPPORTS MORE INFORMED DECISION MAKING…
Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma…
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
August 21, 2025 01:30 ET Â | Source: NICOX SA Press Release Nicox…